Maintenance therapy with three targeted drugs for advanced HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three targeted drugs (pyrotinib plus trastuzumab and pertuzumab) as maintenance therapy to help keep advanced HER2-positive breast cancer under control after initial successful treatment. The goal is to see if this triple-drug approach works better than the standard two-drug maintenance.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with HER2-positive advanced breast cancer (meaning the cancer has spread or cannot be removed with surgery).
- You must have already received a standard first treatment for advanced disease that included trastuzumab, pertuzumab, and a taxane chemotherapy, and your cancer did not grow during or right after that treatment.
- If you have brain metastases, they must be small, not causing symptoms, and not getting worse since you started your first treatment.
- You cannot have taken any prior HER2- or EGFR-targeting pills (like pyrotinib, neratinib, tucatinib) for this disease.
- You must be physically able to care for yourself (able to walk and manage most daily activities, even if you need some help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
This study tests a maintenance therapy (treatment given to keep cancer from growing) for women with HER2-positive breast cancer that has spread or can't be removed. It may help if you haven't had much treatment yet for your advanced cancer.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a treatment for early-stage HER2-positive breast cancer that is small and has not spread to lymph nodes. It aims to reduce the chance of cancer returning after surgery.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.